Tapentadol immediate-release

Drug Profile

Tapentadol immediate-release

Alternative Names: BN-200; CG-5503; Nucynta; Palexia; R-331333; Tapentadol HCl immediate release; Tapentadol hydrochloride; Tapentadol IR; Tapentadol OS

Latest Information Update: 07 May 2015

Price : $50

At a glance

  • Originator Grunenthal
  • Developer Grunenthal; Janssen Research & Development; Ortho-McNeil
  • Class Opioid analgesics; Phenols; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pain
  • Phase III Postoperative pain

Most Recent Events

  • 07 May 2015 No recent reports on development identified - Phase-II for Postoperative pain in USA (IV, infusion)
  • 07 May 2015 No recent reports on development identified - Registered for Pain in Australia (PO, tablet)
  • 07 May 2015 Tapentadol immediate-release is still in registration for Pain in USA (PO, liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top